2020 Revenues ($USD) : $3,094,300,000
2020 R&D spend : $63,800,000
2020 Number of Employees : 15,000
Fiscal Year End : 6/30/2020
Key People : John Chiminski, CEO

The Somerset, N.J.–headquartered company was formed in 2007 when the investment management company the Blackstone Group purchased the pharma technologies and services division of Cardinal Health. Catalent now specializes in drug delivery, biologics, drug manufacturing and gene therapies. In February 2020, it acquired Masthercell Global, a contract developer of cell and gene therapy. The company had a solid financial footing in 2020, delivering record financial results in its fiscal year that ended on June 30. Catalent became a public company in 2014 and joined the S&P 500 index on Sept. 21, 2020. –BB